
    
      This study planned to assess long-term safety and tolerability of QGE031 administered every 4
      weeks for an additional 12 months in patients with allergic asthma who previously completed
      study CQGE031B2201. The study was terminated early due to the efficacy results from an
      interim analysis of the Phase II study CQGE031B2201.
    
  